Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2022 Earnings Call Transcript

And based on that information, I think that will give us a lot more clarity about what other indications we want to prioritize, how aggressively when we want to go after them, what also the payer engagement and experience is going to influence that as well.

Serge Belanger: Okay. One last one. I know the focus is on the U.S. launch, but if you’ve given any more thoughts to European plans for DAXXIFY. Thanks.

Mark Foley: Thanks. Yes, I €“ hey, right now we feel like we’ve got more than we can bite off with the U.S. launch. It’s the biggest market. We’ve got an established field force. We’ve got over 5,000 accounts. We’ve got relationships with. The pricing is the best in this market, and so that’s going to be our focus for now. There’s no doubt that the international market opportunity provides us with additional growth opportunities as we go forward. And so we’ll be very thoughtful about how we move into some of those markets as we move our way through. So stay tuned. But for now and certainly for 2023, our primary focus is going to be on the U.S.

Serge Belanger: Great. Thank you.

Mark Foley: Great.

Operator: That concludes the Revance Therapeutics fourth quarter and full year 2022 financial results and corporate update conference call. We thank you for your participation. You may now disconnect.

Jessica Serra: Goodbye.